LENACAPAVIR

Information current as at:

The pharmaceutical company has not advised whether they intend to proceed or not within 60 days of receiving the ratified PBAC minutes. The process for listing is considered inactive.

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: Sunlenca®
Form and strength:: Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:: Gilead Sciences Pty Limited
Condition/indication: (therapeutic use): Human immunodeficiency virus (HIV)
Listing requested:: Please see PSD for more information
Funding program:: Please see PSD for more information
Request authority level:: Please see PSD for more information
PBAC Submission type:: New listing (Standard Re-entry Pathway)
Comment:: --
Other PBAC consideration:: LENACAPAVIR

Progress Details

Submission received for:: November 2023 PBAC meeting
Opportunity for consumer comment:: Open 26/07/2023 and close 20/09/2023 (see PBS Website)
PBAC meeting:: Held on 01/11/2023
PBAC outcome published:: Recommended (see PBAC Outcomes)
Notice of intent submitted:: Awaiting lodgement from pharmaceutical company
5Lodgement of required documentation:: Has not yet commenced
6Agreement to listing arrangements:: Has not yet commenced
7Government processes:: Has not yet commenced
8Medicine listed on the PBS:: Has not yet occurred

Glossary

PBAC Outcome

PBAC Recommendation:

Please see the Outcomes from the relevant meeting for more information

Public Summary Document:

PBAC Public Summary Documents – November 2023

Case ID

a754

Page last updated

31 March 2026

Return to the Medicine Status Listing

v.9.19